Rockville, Maryland – October 27, 2026 – The global benign prostatic hyperplasia (BPH) treatment market is projected to increase from USD 33.7 billion in 2026 to USD 54.8 billion by 2036, registering a compound annual growth rate (CAGR) of 5.0%, according to Fact.MR. The market is expected to create an incremental opportunity of USD 21.1 billion over the forecast period as demand for medical management and procedural treatment of BPH continues to evolve.

The Fact.MR analysis identifies Astellas Pharma Inc., AbbVie Inc. (Allergan), GlaxoSmithKline, Merck & Co., Pfizer Inc., Eli Lilly and Company, Johnson & Johnson, and Sanofi among the companies participating in the competitive landscape. Their presence reflects the importance of pharmaceutical portfolios, established healthcare relationships, and product development in this market.

For pharmaceutical manufacturers, medical-device companies, healthcare providers, and investors, the outlook highlights opportunities across established drug classes, minimally invasive surgical systems, and laser-based treatment technologies.

Get detailed market forecasts, competitive benchmarking, and pricing trends: 

Key Takeaways: Benign Prostatic Hyperplasia Treatment Market

• Market valuation: USD 33.7 billion in 2026.
• Forecast value: USD 54.8 billion by 2036.
• Market growth: 5.0% CAGR from 2026 to 2036.
• Leading product segment: Alpha blocker therapies, with a 34.7% share in 2026.
• Leading end-use segment: Multispecialty hospitals, accounting for 46.5% of end-use demand in 2026.
• Regional growth opportunities: China is projected to grow at a 5.0% CAGR, followed by the United States at 4.9%.
• Competitive focus: Drug portfolios, treatment technology, regulatory compliance, and access to healthcare markets.

Source: Fact.MR, Benign Prostatic Hyperplasia Treatment Market report, updated June 11, 2026.

What Is Driving the Benign Prostatic Hyperplasia Treatment Market?

Benign prostatic hyperplasia is a non-cancerous enlargement of the prostate that can contribute to urinary symptoms and affect quality of life. Treatment options include medication and procedures designed to relieve symptoms or address prostate enlargement.

An aging male population and increasing diagnosis of BPH support demand for treatment. Greater awareness of available therapies and expanding access to urological services also contribute to the market's long-term outlook.

Pharmaceutical treatment remains an important part of BPH management. Alpha blockers and 5-alpha reductase inhibitors serve different therapeutic purposes, giving manufacturers opportunities to compete across established drug categories. At the same time, minimally invasive interventions and laser-based procedures broaden the options available to patients and clinicians.

For decision-makers, these developments create several areas to evaluate: the balance between pharmaceutical and procedural treatment, the affordability of therapies, the strength of product portfolios, and access to healthcare facilities.

Which Product Segments Lead the BPH Treatment Market?

Alpha blocker therapies account for 34.7% of the product segment in 2026, making them a central category in the Fact.MR market assessment. Their established role in treatment supports continued commercial relevance for manufacturers serving the BPH medication market.

The report also covers 5-alpha reductase inhibitors, minimally invasive surgical systems, and laser therapy systems. These categories address different treatment requirements and create distinct competitive opportunities for pharmaceutical and medical-device suppliers.

Oral drug formulations account for 37.1% of the formulation segment in 2026. This share highlights the importance of oral medicines within the broader treatment landscape.

Manufacturers can use these segment distinctions to assess portfolio gaps, distribution priorities, and product development opportunities. Medical-device suppliers, meanwhile, can evaluate demand for minimally invasive procedures and laser-based treatment platforms without assuming that every patient or clinical setting will adopt the same approach.

Why Are Minimally Invasive Procedures Gaining Attention?

Minimally invasive procedures offer another avenue for competition in BPH treatment. Prostatic urethral lift systems, water vapor therapy systems, and laser-based interventions are among the technologies covered by the report's treatment categories.

These approaches expand the options available to clinicians beyond long-term medication management and conventional surgical procedures. Their commercial prospects depend on clinical suitability, physician familiarity, equipment availability, regulatory requirements, reimbursement arrangements, and treatment costs.

Teleflex, associated with the UroLift System, and Boston Scientific, with its GreenLight laser therapy portfolio, are relevant medical-device participants in this area. Their technologies illustrate how competition extends beyond pharmaceutical products into procedure-based treatment.

For healthcare providers and procurement teams, evaluating these technologies requires consideration of clinical evidence, patient selection, capital expenditure, training requirements, and the overall cost of care.

Which Regions Offer Growth Opportunities?

China is projected to record a 5.0% CAGR between 2026 and 2036, while the United States is expected to grow at 4.9%. France is forecast to expand at 4.7%, the United Kingdom at 4.6%, and Australia at 4.4%.

These country-level projections provide a useful starting point for companies evaluating geographic expansion. They should be considered alongside local healthcare infrastructure, treatment affordability, reimbursement policies, competition from generic medicines, and regulatory requirements.

In the United States, insurance coverage, prescription formularies, and hospital procurement practices can influence treatment selection. In China, centralized drug procurement and the expansion of hospital capacity are relevant factors in market access and pricing.

India also presents a market to assess for affordable treatment options and expanding urological care. Fact.MR's report discusses the role of generic medicines and healthcare access in the country's BPH treatment landscape. However, companies should evaluate country-specific commercial conditions before translating broad market growth into investment decisions.

Who Are the Top Companies in the Benign Prostatic Hyperplasia Treatment Market?

Fact.MR identifies the following companies in its competitive landscape:

1.     Astellas Pharma Inc.

2.     AbbVie Inc. (Allergan)

3.     GlaxoSmithKline

4.     Merck & Co.

5.     Pfizer Inc.

6.     Eli Lilly and Company

7.     Johnson & Johnson

8.     Sanofi

9.     Bayer AG

10.  Teleflex

11.  Boston Scientific Corporation

12.  Olympus

These companies represent pharmaceutical and medical-device participants associated with different parts of the BPH treatment ecosystem. The list is not a market-share ranking, and inclusion does not imply that all companies compete directly in every treatment category.

Competitive positioning depends on the relevance of individual product portfolios, clinical evidence, intellectual property, regulatory approvals, distribution capabilities, and relationships with healthcare providers.

For investors and commercial strategy teams, the distinction between pharmaceutical suppliers and procedure-technology companies is particularly important. Their revenue opportunities, product development cycles, purchasing channels, and market-access requirements can differ considerably.

Business Implications for Manufacturers and Healthcare Buyers

The projected increase from USD 33.7 billion in 2026 to USD 54.8 billion in 2036 gives market participants a measurable basis for long-term planning. The 5.0% CAGR indicates a growing market, although individual companies may experience different outcomes depending on their portfolios and geographic exposure.

Pharmaceutical manufacturers can assess opportunities in established drug classes, generic competition, and treatment affordability. Medical-device companies can examine minimally invasive systems and laser technologies while accounting for clinical adoption and equipment procurement requirements.

Healthcare buyers can compare treatment options through clinical suitability, total cost of care, availability, and provider capabilities. Investors can use segment and country forecasts to identify areas for further due diligence rather than treating overall market expansion as a guarantee of company-level growth.

Read the full report:

Explore More Related Studies Published by Fact.MR Research

Automated Clinical Analyzers Market

Cemiplimab-rwlc Market

Medical Instrument Cabinets Market

About Fact.MR

Fact.MR is a market research and consulting firm providing syndicated research, customized research, investment research, and market intelligence across a broad range of industries. Its research coverage includes food and beverage, healthcare, pharmaceuticals, biotechnology, consumer products, chemicals and materials, technology, industrial goods, and packaging.

Fact.MR provides market intelligence designed to help organizations understand market dynamics, emerging opportunities, competitive developments, and changing industry requirements.

Media Contact

Fact.MR
Email: sales@factmr.com
Phone: +1 (628) 251-1583
Website: www.factmr.com